Vol 73, No 2 (2023)
Review paper
Published online: 2023-03-20

open access

Page views 1889
Article views/downloads 225
Get Citation

Connect on Social Media

Connect on Social Media

Radiotherapy and targeted therapy – a review of the literature

Maksymilian Kruczała12, Beata Sas-Korczyńska1
Nowotwory. Journal of Oncology 2023;73(2):91-94.


Radiotherapy (RT) is an important treatment modality for cancer treatment patients. Approximately 50% of all cancer patients receive RT during the course of their illness. A great potential to improve treatment results involves combination RT with other methods. The combination of RT and cytotoxic chemotherapy is a clinically well-established and documen­ted method to improve survival. Integration of targeted therapy with RT may provide therapeutic benefit by exploiting biologic and genetic differences between cancer and normal tissues while minimizing additional toxicity. The aim of this paper is to present a literature review of the effectiveness of combination radiotherapy and molecular targeted therapy.

Article available in PDF format

View PDF Download PDF file


  1. Delaney G, Jacob S, Featherstone C, et al. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005; 104(6): 1129–1137.
  2. Elbanna M, Chowdhury NN, Rhome R, et al. Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy. Front Oncol. 2021; 11: 749496.
  3. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009; 461(7267): 1071–1078.
  4. Vasan N, Carlo MI. Pocket Oncology. 2nd edition. Wolters Kluwer 2019.
  5. Baskar R, Lee KA, Yeo R. Cancer and radiation therapy: current advances and future directions. Int J Med Scie. 2012; 9(3): 193–199.
  6. Pavlopoulou A, Bagos PG, Koutsandrea V, et al. Molecular determinants of radiosensitivity in normal and tumor tissue: A bioinformatic approach. Cancer Lett. 2017; 403: 37–47.
  7. Sato N, Mizumoto K, Nakamura M, et al. A possible role for centrosome overduplication in radiation-induced cell death. Oncogene. 2000; 19(46): 5281–5290.
  8. Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ. 2008; 15(7): 1153–1162.
  9. Jonathan EC, Bernhard EJ, McKenna WG. How does radiation kill cells? Curr Opin Chem Biol. 1999; 3(1): 77–83.
  10. Dewey WC, Ling CC, Meyn RE. Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys. 1995; 33(4): 781–796.
  11. Rupnow BA, Knox SJ. The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. Apoptosis. 1999; 4(2): 115–143.
  12. Cragg MS, Harris C, Strasser A, et al. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer. 2009; 9(5): 321–326.
  13. Hotchkiss R, Strasser A, McDunn J, et al. Cell death. N Engl J Med. 2009; 361(16): 1570–1583.
  14. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res. 2003; 63(11): 2705–2715.
  15. Schmitt CA. Cellular senescence and cancer treatment. Biochim Biophys Acta. 2007; 1775(1): 5–20.
  16. Kuwahara Y, Oikawa T, Ochiai Y, et al. Enhancement of autophagy is a potential modality for tumors refractory to radiotherapy. Cell Death Dis. 2011; 2(6): e177.
  17. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011; 11(4): 239–253.
  18. Hall EJ. Cancer caused by x-rays--a random event? Lancet Oncol. 2007; 8(5): 369–370.
  19. Baskar R. Emerging role of radiation induced bystander effects: Cell communications and carcinogenesis. Genome Integr. 2010; 1(1): 13.
  20. Lawrence YR, Vikram B, Dignam JJ, et al. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst. 2013; 105(1): 11–24.
  21. Ataman OU, Sambrook SJ, Wilks C, et al. The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective. Int J Radiat Oncol Biol Phys. 2012; 84(4): e447–e454.
  22. Padma VV. An overview of targeted cancer therapy. Biomedicine (Taipei). 2015; 5(4): 19.
  23. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6): 567–578.
  24. Mehanna H, Robinson M, Hartley A, et al. De-ESCALaTE HPV Trial Group. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019; 393(10166): 51–60.
  25. Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019; 393(10166): 40–50.
  26. Iannitti D, Dipetrillo T, Akerman P, et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol. 2005; 28(6): 570–575.
  27. Duffy A, Kortmansky J, Schwartz GK, et al. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol. 2008; 19(1): 86–91.
  28. Ma WW, Herman JM, Jimeno A, et al. A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Transl Oncol. 2010; 3(6): 373–379.
  29. Bao PQ, Ramanathan RK, Krasinkas A, et al. Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol. 2011; 18(4): 1122–1129.
  30. Herman JM, Fan KY, Wild AT, et al. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013; 86(4): 678–685.
  31. Ma DJ, Galanis E, Anderson SK, et al. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol. 2015; 17(9): 1261–1269.
  32. Chinnaiyan P, Won M, Wen PY, et al. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neuro Oncol. 2018; 20(5): 666–673.
  33. Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol. 1998; 46(2): 135–146.
  34. Hoskin PJ, Rojas AM, Bentzen SM, et al. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol. 2010; 28(33): 4912–4918.
  35. Janssens GO, Rademakers SE, Terhaard CH, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol. 2012; 30(15): 1777–1783.
  36. DiSilvestro PA, Ali S, Craighead PS, et al. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study. J Clin Oncol. 2014; 32(5): 458–464.
  37. Jagsi R, Griffith KA, Bellon JR, et al. Translational Breast Cancer Research Consortium. Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study. J Clin Oncol. 2018; 36(13): 1317–1322.
  38. Tuli R, Shiao SL, Nissen N, et al. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine. 2019; 40: 375–381.
  39. Karam SD, Reddy K, Blatchford PJ, et al. Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2018; 24(20): 4949–4959.
  40. Cuneo KC, Morgan MA, Sahai V, et al. Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer. J Clin Oncol. 2019; 37(29): 2643–2650.
  41. Bonvalot S, Rutkowski PL, Thariat J, et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. Lancet Oncol. 2019; 20(8): 1148–1159.

Nowotwory. Journal of Oncology